Business Overview

Mar 2019
Date Founded
Active
Operating Status
4
Employees

PatenSee is developing a novel machine-learning-based surveillance tool for end-stage renal disease (ESRD) patients who are on hemodialysis treatment. PatenSees solution is being developed to seamlessly integrate into the clinic workflow and detect early signs of vascular access stenosis to allow preventative, and less costly, intervention. Early detection will help the patient avoid costly procedures and complications such as infection and minimize dialysis treatment interruption.PatenSee was founded by Hagay Drori following his participation in MEDX Xelerators X-Challenge competition, the incubators initiative to create promising medical device startups developing breakthrough solutions that can impact patients lives and improve healthcare systems.

Business Stage
Product Development

Founders

PatenSee
Gal Goshen
CEO

Board Members and Advisors

PatenSee
Shay Policker
Board Member

AI Technology Stack

Vertical AI
AI Application

More Startups

AI Team Ratio
STATUS
Active
AI Team Ratio
STATUS
Active
FUNDING
$243 M
FUNDING STAGE
Series B
AI Team Ratio
STATUS
Inactive
STATUS
Active
AI Team Ratio
STATUS
Active
AI Team Ratio
STATUS
Active
FUNDING
$2.5 M
FUNDING STAGE
Seed
STATUS
Acquired
AI Team Ratio
STATUS
Active
FUNDING
$0.8 M
FUNDING STAGE
Seed
AI Team Ratio
STATUS
Active
FUNDING
$2.3 M
FUNDING STAGE
Seed
STATUS
Active
FUNDING
$11.5 M
FUNDING STAGE
Series A
AI Team Ratio
STATUS
Active
FUNDING
$17 M
FUNDING STAGE
Series A
STATUS
Active
STATUS
Active
AI Team Ratio
STATUS
Active
FUNDING
$37 M
FUNDING STAGE
Series B
AI Team Ratio
STATUS
Active
FUNDING
$9.6 M
FUNDING STAGE
Series B

Startup Snapshot

Operating Status
Active
AI Team Size
0
Total Funding
$0 Million
Founded
March 2019

Competitors

Add competitors to PatenSee

Sign up for free

  • Save profiles to your list
  • View all funding rounds
  • Advanced sorting filter access
  • Search investment rounds
  • Search exit events

Fundraising Contact

Submission Received

Thanks for your contribution.

Your edits are under review and will be visible soon.